Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q1 FY23 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Aug 10, 2022
Slide 1: Exchange filing cover letter for investor presentation
August 10, 2022 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please find atta
Slide 2: Zydus Lifesciences Limited Earnings Presentation
Zydus Lifesciences Limited Earnings Presentation 10th August, 2022 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q1 FY23: Financial Performance
Q1 FY23: Financial Performance Total Revenues* R&D Key Highlights of Q1 FY23 ❑ Ex-COVID related business, total revenues grew 11% yoy. Rs. 40,727 mn Rs. 2,842 mn ❑ Branded portfolio of India formulations business continued to progress 2% YoY 7% of revenues well (up 9% yoy, ex-COVID) with market shar
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) 26,468 25,634 40,018 40,727 37,598 38,638 23,988 23,679 36,398 23,064 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Total R&D (Rs. mn) and % to Revenues EBITDA ex. one-offs (Rs. mn) and Margin % 7.3% 5.
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional, One-offs and Discontinued ops.(Rs. mn) Capex (Rs. mn) 6,697 5,972 3,100 5,250 5,295 2,800 2,828 5,069 2,650 2,668 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Net Debt/ EBITDA Net Working Capital* (Rs. mn) 51,218 48,765 49,219
Slide 7: India Formulations business
India Formulations business Focus on execution to accelerate growth Highlights for the quarter India Formulations Sales (Rs. mn) Q1 FY23 Revenue ▪ Branded prescription business grew by 9% YoY, Contribution 13,566 ex-COVID opportunities, Gx portfolio and divested 12,134 10,785 11,640 11,251 products,
Slide 8: Consumer Wellness
Consumer Wellness The business rebounded and registered strong growth Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q1 FY23 Revenue Contribution ▪ Timely onset of summer and improved distribution 6,330 6,916 reach helped to re-recruit consumers for summer 5,862 heavy brands like Glucon
Slide 9: US Formulations business
US Formulations business Consolidating the position amidst challenging environment Highlights for the quarter US Formulations Sales (Rs. mn) Q1 FY23 Revenue ▪ Maintained top 3 ranking in ~ 60% of the product Contribution families in the US. 14,734 14,892 15,592 14,279 14,233 ▪ Received 7 new product
Slide 10: Emerging Markets Formulations business
Emerging Markets Formulations business Base business continued to display growth Highlights for the quarter EM Formulations Sales (Rs. mn) Q1 FY23 Revenue Contribution ▪ With receding impact of pandemic, the business grew 3,487 3,155 in double digit. The growth was broad based across 2,914 2,770 2,7
Slide 11: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • Global pivotal Phase II(b)/III CT viz. EPICS-IIITM to evaluate the efficacy and safety of the molecule in patients with PBC and Phase II global CT for NASH/ Fibrosis are ongoing for the US market. • Clinical trials are currently ongoing for PCOS an
Slide 12: Updates on Innovation
Updates on Innovation Biosimilars • Received marketing approval for drug substance of biosimilar Adalimumab from the Russian regulatory authority. • Continue to file new products in existing emerging market countries and enter new markets through partnerships to ensure long-term, sustainable growth
Slide 13: Zydus at a Glance
Zydus at a Glance >$2 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Over Among 1st Revenues from branded Approved product for In 60% of product 50% business (India, EM and Top 3 families marketed in
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q1 Q1 YoY Q4 QoQ Rs. mn FY23 FY22 gr. FY22 gr. Comments for Q1 FY23: Total Income from Ops. 40,727 40,018 1.8% 38,638 5.4% Gross Contribution (GC) 25,634 26,468 -3.2% 23,680 8.3% • YoY decline in GC is due to Gross Margin % 62.9% 66.1% 61.3% pricing pres
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q1 Q1 YoY Rs. mn FY23 FY22 gr. A. On operating transactions (above EBIDTA line) -998 -481 -107.6% a. Included in other operating income -1,083 -527 -105.5% b. Included in COGS 86 47 83.9% c. Included in other operating expenses - - B. On other income -149 -182 1
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-79-71800839 For more information, please visit www.zyduslife.com Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway,